Search the Newsreel

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Cytokinetics (CYTK) has received an upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This rating change signifies a positive outlook for the company's earnings and could lead to increased buying pressure and stock price appreciation. The …

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11%

Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates

Earnings Beat: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Earnings call transcript: Cytokinetics Q1 2026 results show revenue surge

Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates